Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Beyond the Basics: Unique Markers May Assist in Morphologic Classification

August 21st 2012

The presence of specific molecular biomarkers may assist in determining the correct morphologic diagnosis of the particular cancer being examined.

Suzanne Fuqua on Utilizing Predictive Biomarkers

August 21st 2012

Suzanne Fuqua, PhD, from the Baylor College of Medicine, on the Utilization of Predictive Biomarkers

Elaine Mardis on Sensitivity to Aromatase Inhibitors

August 20th 2012

Elaine Mardis, from the Genome Institute at Washington University School of Medicine, on Sensitivity to Aromatase Inhibitors

Exploring Ways to Broaden the Reach of Molecular Tumor Testing

August 17th 2012

The development of targeted therapies for a variety of tumor types has highlighted a greater need for widespread molecular testing to determine which patients have the mutations that these therapies target.

Dr. Herbst Explores Molecular Testing in Lung Cancer

August 15th 2012

Dr. Roy S. Herbst, from Yale Cancer Center, Explores Molecular Testing in Lung Cancer

Ranking Value in Cancer Care: Analysis of a "Pathways" Approach

August 13th 2012

Amid a continuing debate over healthcare spending in the United States, the oncology community is growing more introspective about the costs associated with increasingly sophisticated cancer therapeutics.

Dr. Gandara Discusses Molecular Testing for NSCLC

August 9th 2012

Dr. David Gandara, from University of California, Davis Comprehensive Cancer Center, discusses using the multiplexing assay for patients with non-small cell lung cancer

Tivantinib Achieves Advantage for Patients With HCC

August 9th 2012

Tivantinib has demonstrated statistically significant improvements in time to progression and overall survival versus placebo among patients with unresectable hepatocellular carcinoma.

ASCO Launches Mentor Program With Grant to Noted Researcher

August 8th 2012

An effort to nurture the drug development skills of young oncologists as they explore a novel targeted agent has gained support from the Conquer Cancer Foundation of the American Society of Clinical Oncology.

5 PARP-Related Questions for Melinda L. Telli, MD

August 2nd 2012

Melinda L. Telli, MD, is actively involved in clinical research that focuses on DNA repair targeted therapeutics for the treatment of triple-negative and BRCA1/2 mutation-associated breast cancer.

TS Expression Explored in ALK-positive NSCLC

August 1st 2012

Expression levels of thymidylate synthase may help point the way to new treatment options for patients with ALK-positive NSCLC, including combination therapy.

The PARP Inhibitors: Down But Not Out

July 31st 2012

In spite of the setbacks, researchers remain hopeful that a better understanding of the mechanism of action for PARP inhibitors will lead to effective treatment of a wide variety of cancers.

Putting Key Developments in Two Tumor Types in Focus

July 27th 2012

As the molecular understanding of breast cancer continues to evolve, the search for treatment targets based upon tumor subtypes and gene expression patterns is intensifying.

Sipuleucel-T Studies Support Earlier Use, Reveal Potential Biomarker

July 25th 2012

Research presented at ASCO 2012 examined the expanded use of sipuleucel-T, as well as methods to determine which patients might benefit the most from the therapy.

Dr. Rotkowitz Defines Personalized Medicine

July 23rd 2012

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, Defines Personalized Medicine

Dr. Anthony on Targeted Therapy Associated Diarrhea

July 16th 2012

Dr. Lowell Anthony from the University of Kentucky Markey Cancer Center on Targeted Therapy Associated Diarrhea.

FDA Approves Cetuximab Plus FOLFIRI for Metastatic Colorectal Cancer

July 10th 2012

The FDA has approved cetuximab in combination with the FOLFIRI regimen as a first-line treatment for patients with mCRC who express EGFR and wild-type KRAS mutations.

Five Questions for Hans-Peter Gerber, PhD

July 10th 2012

Hans-Peter Gerber has been building a program to develop novel biotherapeutics for oncology, including antibody-drug conjugates, at the Pfizer Oncology Research Unit in Pearl River, New York.

Dr. Kris on the Combination of Targeted Therapies

July 6th 2012

Dr. Mark Kris, from Memorial Sloan-Kettering Cancer Center, on the Combination of Molecularly Targeted Therapies.

University of Chicago Comprehensive Cancer Center: Innovation in Research

July 6th 2012

For nearly 40 years, the University of Chicago Comprehensive Cancer Center has enjoyed a reputation for excellence and innovation.